|
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozumab was developed by Eli Lilly and Company. == References == 〔 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Blosozumab」の詳細全文を読む スポンサード リンク
|